Anivive's Valley Fever Vaccine Receives Major Funding Boost from NIH
National Institute of Allergy and Infectious Diseases Awards Contract Worth Up to $33 Million
One Health Technology Company to Utilize Underlying Science for Canine Valley Fever Vaccine Development
WEB Anivive Lifesciences, a US-based pharmaceutical company dedicated to advancing animal health, has secured a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), valued at up to $33 million.
This contract aims to harness the scientific advancements underlying Anivive's animal health Valley Fever vaccine for dogs. Valley Fever, caused by the Coccidioides fungus, is a prevalent disease in the southwestern United States and can have severe consequences for dogs.
Anivive's Valley Fever vaccine for dogs is currently in clinical trials and has shown promising results in preventing or mitigating the effects of the disease. The funding from NIAID will enable Anivive to further develop and commercialize the vaccine, potentially bringing much-needed protection to dogs and their owners.
This project is part of a broader effort by NIAID to support the development of vaccines and therapeutics for emerging and re-emerging infectious diseases. The Canine Valley Fever Vaccine Project is a joint public-private venture that includes the Valley Fever Center for Excellence at the University of California, Davis, and the California Department of Food and Agriculture.
Comments